Robert Holaj

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/6935819/publications.pdf

Version: 2024-02-01

56 5,368 25 48 papers citations h-index g-index

57 57 57 5802 all docs docs citations times ranked citing authors

#	Article	IF	CITATIONS
1	Gene Profile of Adipose Tissue of Patients with Pheochromocytoma/Paraganglioma. Biomedicines, 2022, 10, 586.	1.4	3
2	Adherence and blood pressure control in patients with primary aldosteronism. Blood Pressure, 2022, 31, 58-63.	0.7	1
3	Epithelioid sarcoma with retained INI1 expression as a cause of a chronic leg ulcer. SAGE Open Medical Case Reports, 2022, 10, 2050313X2211062.	0.2	1
4	Adrenal Venous Sampling Could Be Omitted before Surgery in Patients with Conn's Adenoma Confirmed by Computed Tomography and Higher Normal Aldosterone Concentration after Saline Infusion Test. Diagnostics, 2022, 12, 1718.	1.3	6
5	Postoperative adrenal insufficiency in Conn's syndromeâ€"does it occur frequently?. Journal of Human Hypertension, 2021, , .	1.0	2
6	Effect of adrenalectomy on remission of subclinical left ventricular dysfunction in patients with pheochromocytoma: a speckle-tracking echocardiography study. Endocrine Connections, 2021, 10, 1538-1549.	0.8	5
7	Cancer Development and Damped Electromagnetic Activity. Applied Sciences (Switzerland), 2020, 10, 1826.	1.3	2
8	Primary Aldosteronism and Pregnancy. Kidney and Blood Pressure Research, 2020, 45, 275-285.	0.9	16
9	Pheochromocytoma With Adrenergic Biochemical Phenotype Shows Decreased GLP-1 Secretion and Impaired Glucose Tolerance. Journal of Clinical Endocrinology and Metabolism, 2020, 105, 1878-1887.	1.8	13
10	Blood Pressure Profile, Catecholamine Phenotype, and Target Organ Damage in Pheochromocytoma/Paraganglioma. Journal of Clinical Endocrinology and Metabolism, 2019, 104, 5170-5180.	1.8	28
11	Catecholamines Induce Left Ventricular Subclinical Systolic Dysfunction: A Speckle-Tracking Echocardiography Study. Cancers, 2019, 11, 318.	1.7	13
12	FGF21 Levels in Pheochromocytoma/Functional Paraganglioma. Cancers, 2019, 11, 485.	1.7	2
13	(Prediction of long-term renal denervation efficacy). Cor Et Vasa, 2019, 61, e378-e384.	0.1	O
14	LONG-TERM EFFECT OF ADRENALECTOMY ON CARDIOVASCULAR REMODELING IN PATIENTS WITH PHEOCHROMOCYTOMA. Journal of Clinical Endocrinology and Metabolism, 2017, 102, jc.2016-2422.	1.8	14
15	Renal denervation in comparison with intensified pharmacotherapy in true resistant hypertension. Journal of Hypertension, 2017, 35, 1093-1099.	0.3	25
16	Risk Factors for Nonadherence to Antihypertensive Treatment. Hypertension, 2017, 69, 1113-1120.	1.3	150
17	Extended Thromboprophylaxis with Betrixaban in Acutely III Medical Patients. New England Journal of Medicine, 2016, 375, 534-544.	13.9	379
18	Should All Patients with Resistant Hypertension Receive Spironolactone?. Current Hypertension Reports, 2016, 18, 81.	1.5	6

#	Article	IF	CITATIONS
19	Combination antihypertensive therapy in clinical practice. The analysis of 1254 consecutive patients with uncontrolled hypertension. Journal of Human Hypertension, 2016, 30, 35-39.	1.0	19
20	Laparoscopic adrenalectomy: institutional Czech experience after almost 300 operations. European Surgery - Acta Chirurgica Austriaca, 2016, 48, 121-124.	0.3	0
21	Role of Adding Spironolactone and Renal Denervation in True Resistant Hypertension. Hypertension, 2016, 67, 397-403.	1.3	73
22	Current approaches to combination therapy of hypertension. Interni Medicina Pro Praxi, 2016, 18, 168-175.	0.0	0
23	Long-term effect of specific treatment of primary aldosteronism on carotid intima–media thickness. Journal of Hypertension, 2015, 33, 874-882.	0.3	35
24	Long-term effects of adrenalectomy or spironolactone on blood pressure control and regression of left ventricle hypertrophy in patients with primary aldosteronism. JRAAS - Journal of the Renin-Angiotensin-Aldosterone System, 2015, 16, 1109-1117.	1.0	29
25	Biochemical Testing After Pheochromocytoma Removal: How Early?. Hormone and Metabolic Research, 2015, 47, 633-636.	0.7	1
26	Randomized Comparison of Renal Denervation Versus Intensified Pharmacotherapy Including Spironolactone in True-Resistant Hypertension. Hypertension, 2015, 65, 407-413.	1.3	178
27	Importance of thorough investigation of resistant hypertension before renal denervation: should compliance to treatment be evaluated systematically?. Journal of Human Hypertension, 2014, 28, 684-688.	1.0	23
28	Diet and Kidney Disease in High-Risk Individuals With Type 2 Diabetes Mellitus. JAMA Internal Medicine, 2013, 173, 1682-92.	2.6	100
29	Apixaban for Extended Treatment of Venous Thromboembolism. New England Journal of Medicine, 2013, 368, 699-708.	13.9	1,116
30	Oral Apixaban for the Treatment of Acute Venous Thromboembolism. New England Journal of Medicine, 2013, 369, 799-808.	13.9	1,915
31	Changes in Energy Metabolism in Pheochromocytoma. Journal of Clinical Endocrinology and Metabolism, 2013, 98, 1651-1658.	1.8	49
32	Precise assessment of noncompliance with the antihypertensive therapy in patients with resistant hypertension using toxicological serum analysis. Journal of Hypertension, 2013, 31, 2455-2461.	0.3	136
33	Vascular Disturbances in Primary Aldosteronism: Clinical Evidence. Kidney and Blood Pressure Research, 2012, 35, 529-533.	0.9	30
34	High Incidence of Cardiovascular Complications in Pheochromocytoma. Hormone and Metabolic Research, 2012, 44, 379-384.	0.7	138
35	Left ventricle remodeling in men with moderate to severe volume-dependent hypertension. JRAAS - Journal of the Renin-Angiotensin-Aldosterone System, 2012, 13, 426-434.	1.0	8
36	Discrepant Results of Adrenal Venous Sampling in Seven Patients with Primary Aldosteronism. Kidney and Blood Pressure Research, 2012, 35, 205-210.	0.9	14

#	Article	IF	Citations
37	Pulse wave velocity in primary hyperparathyroidism and effect of surgical therapy. Hypertension Research, 2011, 34, 296-300.	1.5	42
38	How to assess non-compliance with the pharmacotherapy in severe resistant hypertension?. Cor Et Vasa, 2011, 53, 429-432.	0.1	1
39	Is target organ damage more frequent in primary aldosteronism than in essential hypertension?. Cor Et Vasa, 2011, 53, 449-453.	0.1	0
40	Determination of doxazosin and verapamil in human serum by fast LC–MS/MS: Application to document non-compliance of patients. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2010, 878, 3167-3173.	1.2	26
41	The prevalence of metabolic syndrome and its components in two main types of primary aldosteronism. Journal of Human Hypertension, 2010, 24, 625-630.	1.0	57
42	Factors influencing arterial stiffness in pheochromocytoma and effect of adrenalectomy. Hypertension Research, 2010, 33, 454-459.	1.5	34
43	Erectile Dysfunction Predicts Cardiovascular Events in High-Risk Patients Receiving Telmisartan, Ramipril, or Both. Circulation, 2010, 121, 1439-1446.	1.6	172
44	Increased carotid intima-media thickness in patients with pheochromocytoma in comparison to essential hypertension. Journal of Human Hypertension, 2009, 23, 350-358.	1.0	15
45	Creation of dialysis vascular access with normal flow increases brain natriuretic peptide levels. International Urology and Nephrology, 2009, 41, 997-1002.	0.6	6
46	INCREASED CAROTID INTIMA MEDIA THICKNESS IN PATIENTS WITH PHEOCHROMOCYTOMA IN COMPARISON TO ESSENTIAL HYPERTENSION. Atherosclerosis Supplements, 2008, 9, 158.	1.2	0
47	Adrenalectomy Improves Arterial Stiffness in Primary Aldosteronism. American Journal of Hypertension, 2008, 21, 1086-1092.	1.0	89
48	Increased carotid intima–media thickness in hypertensive patients with a high aldosterone/plasma renin activity ratio and elevated aldosterone plasma concentration. Journal of Hypertension, 2008, 26, 1500-1501.	0.3	2
49	Elevated Inflammation Markers in Pheochromocytoma Compared to Other Forms of Hypertension. NeuroImmunoModulation, 2007, 14, 57-64.	0.9	38
50	Increased intima–media thickness of the common carotid artery in primary aldosteronism in comparison with essential hypertension. Journal of Hypertension, 2007, 25, 1451-1457.	0.3	85
51	We-P11:195 Comparison of carotid intima-media thickness in patients with primary and secondary hypertension. Atherosclerosis Supplements, 2006, 7, 389.	1.2	0
52	Increased Arterial Wall Stiffness in Primary Aldosteronism in Comparison With Essential Hypertension. American Journal of Hypertension, 2006, 19, 909-914.	1.0	96
53	The Inverse Association of Elevated Serum Bilirubin Levels with Subclinical Carotid Atherosclerosis. Cerebrovascular Diseases, 2006, 21, 408-414.	0.8	96
54	Increased blood pressure variability in pheochromocytoma compared to essential hypertension patients. Journal of Hypertension, 2005, 23, 2033-2039.	0.3	45

Robert Holaj

#	Article	IF	CITATIONS
55	Intima-media thickness of the common carotid artery is the significant predictor of angiographically proven coronary artery disease. Canadian Journal of Cardiology, 2003, 19, 670-6.	0.8	34
56	The effect of perindopril on arterial stiffness and endothelial function in patients with stable coronary artery disease. Atherosclerosis, 1999, 144, 54-55.	0.4	0